Using a transgenic mouse model of prostate cancer, Isayeva et al (2007) demonstrated that inhibitors of the VEGF2 receptor delayed tumour progression only when administered in the early stages of prostate cancer, before a significant rise in VEGF levels was observed. Here, VEGFA is linked to prostate carcinoma.